Monday, February 15, 2021

GERN stock: The Geron Corp/J&J Saga is a Valuable Lesson for Investors

 Feb. 15, 2021

Here is the link. 

Disappointing news that Johnson & Johnson (NYSE: JNJ) decided to walk away from a collaboration with Geron Corp. (NASDAQ: GERN) on its only drug, imetelstat, has sent Geron’s shares reeling and cast doubt on its future. In this clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell dissect what happened to help investors avoid companies with similar risks.

Phase three trial - go alone - 2018

90% clinical trial failed

65 million milestone payment -

No comments:

Post a Comment